Contrast sensitivity in MS: what the research says

Most people with multiple sclerosis encounter their visual pathway at some point. Optic neuritis is the presenting symptom in roughly a fifth of cases and shows up clinically in something close to half of all patients over time;¹ subclinical demyelination — nerve damage happening quietly, below the threshold of a noticed symptom — of the optic nerve and the pathways behind it is more common still, picked up on imaging or on visual evoked potentials (a test that times the electrical signal travelling from eye to visual cortex) in people who have never had a named visual event. None of that necessarily shows up on the eye chart. Visual acuity recovers, often to 20/20 or better, in the large majority of optic-neuritis episodes — but the visual system does not return to its pre-attack state when it does.

The measurement that registers the difference is contrast sensitivity. It samples a richer range of visual function than acuity, and in MS it is reduced more often than acuity is, in eyes both with and without a history of named optic neuritis. The rest of this post is about what the literature actually shows about contrast sensitivity in MS, what it can and can't tell you when you measure it on your own setup at home, and how to use it as a thread of evidence alongside the rest of your clinical record.

Why contrast sensitivity is a sensitive probe

Demyelination — the loss of the fatty myelin sheath that insulates nerve fibres and lets them fire quickly and in step — changes the conduction properties of axons. Nerve impulses propagate more slowly, more variably from one fibre to the next, and at lower amplitudes than they do in healthy myelinated tissue. In the optic nerve, that translates into a temporally smeared, partially-attenuated signal arriving at the lateral geniculate (the visual relay station deep in the brain) and visual cortex. High-contrast stimuli — the black letters of an eye chart against a bright white page — drive the surviving fibres strongly enough that the reduced signal can still be reconstructed at a recognisable level. Low-contrast stimuli — the faint patterns of edges and gradients that make up most of the visual world — do not have that margin to work with. Detecting them depends on the visual system pulling a weak signal out of its noise floor, and the noise floor goes up when conduction is degraded.

This is why contrast sensitivity often remains reduced after an optic neuritis episode has "resolved" by acuity criteria. Trobe and colleagues, working with the Optic Neuritis Treatment Trial (ONTT) cohort, compared four vision tests — Snellen acuity, Pelli-Robson contrast sensitivity, Humphrey perimetry, and Farnsworth-Munsell 100-hue colour vision — six months after an acute optic neuritis attack. Contrast sensitivity was the most likely of the four to be abnormal at six months, roughly 2.2 times more often than acuity, 1.8 times more often than perimetry (visual-field testing), and 1.5 times more often than colour vision.² Crucially, those are six-month figures — measured after visual recovery had already occurred, with acuity back to 20/20 or better in the majority of affected eyes. Even then, contrast sensitivity was the test still most likely to register an abnormality. The pattern is consistent: acuity is a relatively sturdy measurement that recovers well; contrast sensitivity is a more sensitive one that records the residual.

The same logic extends beyond named optic-neuritis episodes. Eyes with no clinical history of optic neuritis in MS patients still show contrast-sensitivity reductions compared to disease-free controls, presumably because subclinical demyelination is doing the same conduction-degrading work that the named events do, just below the threshold for noticing. A measurement that picks that up is a useful one, especially in a condition where lesion load on imaging does not map cleanly onto how the person is doing day to day.

What the literature shows

The MS-vision literature is large and growing; what follows is a careful tour of four anchors that are worth knowing about specifically, with one paragraph each.

Low-contrast letter acuity as a visual outcome measure. Balcer and colleagues, in a 2003 paper in Neurology, made the case for adding low-contrast letter acuity (LCLA) — Sloan charts read at 2.5% and 1.25% contrast — to the Multiple Sclerosis Functional Composite (MSFC), the standard quantitative endpoint used in MS clinical trials at the time. The MSFC had walking, hand function, and cognition components but no measure of vision. The proposal was that LCLA captured visual function that acuity alone did not: in that study, low-contrast Sloan letters and Pelli-Robson contrast sensitivity were the two measures that best separated MS patients from disease-free controls, ahead of high-contrast acuity and colour vision.³ Low-contrast letter acuity and contrast sensitivity overlap conceptually — both ask how visible a low-contrast target is — and the MS literature uses both terms, sometimes interchangeably and sometimes for slightly different measurement procedures.

Longitudinal predictive value. A follow-up in 2005, also in Neurology, looked at whether LCLA scores measured at one time point predicted what happened later. The answer was yes: low-contrast letter acuity correlated with a brain-atrophy measure (brain parenchymal fraction on MRI) and with disability scales, and a change in low-contrast letter acuity over a year predicted subsequent disability progression even after accounting for change in the standard MS composite score.⁴ The clinically interesting implication is that the visual system is acting as a window onto disease activity that is going on elsewhere — not just measuring vision for its own sake, but registering a system-wide signal in a particularly accessible place.

Linking the functional change to structural change with OCT. Optical coherence tomography (OCT) measures the thickness of the retinal nerve fibre layer (RNFL) at the back of the eye — the bundle of unmyelinated axons that converge to form the optic nerve. RNFL thinning is a structural marker of axonal loss in the optic-nerve pathway. Fisher and colleagues, in Ophthalmology in 2006, asked how RNFL thickness related to visual function in MS. They studied 90 MS patients and 36 disease-free controls; MS eyes had thinner RNFL than controls on average, and eyes with a history of optic neuritis had the thinnest of all. For every one-line decrease in low-contrast letter acuity or in Pelli-Robson contrast sensitivity, mean RNFL thickness fell by about 4 µm.⁵ The functional measurement was tracking a structural change. That correlation is part of why low-contrast measures of vision are taken seriously as secondary endpoints in MS clinical trials, rather than dismissed as soft outcomes.

Persistent contrast loss after recovered acuity. Returning to the ONTT thread: the finding worth holding onto from Trobe's 1996 paper is that, even after acuity has recovered, contrast sensitivity is the vision test most likely to stay abnormal — at six months, roughly twice as often as acuity.² The recovery curves for acuity and for contrast sensitivity are not the same curve; the visual system surfaces back toward acuity-normal faster and more completely than it surfaces back toward contrast-normal. If you have had optic neuritis and have been told your acuity has recovered, the literature suggests your contrast sensitivity in that eye may still be measurably reduced compared to your fellow eye or to age-matched controls, even if you don't notice it from one day to the next.

A few other patterns are worth knowing about because they shape what to expect from your own measurements. Asymmetry between eyes is common — optic neuritis is most often unilateral, so an MS eye with a history of named attack and a fellow eye without one can show measurably different contrast sensitivity, and that difference can persist for years. The pattern across spatial frequencies is often broad rather than narrow, with reductions across the mid range of the contrast sensitivity function rather than a single-frequency notch. And the change over time — the slope of contrast sensitivity from one measurement to the next — is often the most useful clinical question, more so than any single absolute number.

The honest summary: contrast sensitivity is reduced in MS more often than acuity is, the reductions correlate with structural change visible on OCT, and changes over time carry signal about disease activity beyond what acuity alone records. None of this turns a contrast measurement into a diagnostic test for MS or for any specific MS subtype. It's a functional probe of an axis the eye chart doesn't sample, and it's a useful one.

What it can tell you as a person with MS

A single contrast-sensitivity measurement is a snapshot. What makes the measurement useful is the line you can draw through multiple snapshots taken on similar terms.

Take it now, save the result, retake it on a regular cadence. For most people, monthly retests on the same setup land in a useful place — frequent enough to register change at the timescale at which MS changes; not so frequent that the day-to-day noise dominates the signal. If you are in an active phase, more often is reasonable. If you are stable, less often is fine. The goal is a track, not a daily number.

Set up baselines around the things you care about. If you are starting or changing a disease-modifying therapy, taking a baseline contrast measurement before the change — and then resampling at one, three, and six months — gives you a curve to look at. If you have had relapses in the past, taking measurements during a stable interval gives you the comparison line you would want to have if a relapse happens later. Several MS patients we have heard from describe the experience of trying to remember what their vision was like before an attack and not having a number to compare against; the practical use of a home tracking tool is to make sure that comparison is available when you next need it.

Bring the trend to your clinicians. A neuro-ophthalmologist, an MS neurologist, or a clinic that uses low-contrast Sloan letters as part of their standard exam is the right audience for the curve. Many MS clinics already use 2.5% and 1.25% Sloan charts in routine visits, and they will recognise the family of measurement. The number from a home test is not a substitute for the in-clinic measurement, which is more tightly controlled. The trend, taken over months on the same setup, is the part that adds information your clinic visit otherwise can't reconstruct.

One honest constraint about our current version. The most sensitive use of contrast sensitivity in MS is per-eye, because optic neuritis and subclinical optic-pathway change are usually asymmetric and a binocular measurement averages over the asymmetry. The v0 of our test is binocular only. Per-eye monocular testing is on the roadmap (see the PRD and the Phase-1 product list) but is not yet in production. If you have a strong reason to test each eye separately — for example, an eye with a history of optic neuritis you want to track distinct from your other eye — a clinic-administered Pelli-Robson or low-contrast Sloan chart will give you that data. Our test will give you a binocular number, which still tracks change over time on the same setup, but it will under-record an asymmetric loss compared to per-eye testing.

For the same reason, treat any single home measurement with appropriate humility. Day-to-day noise in MS vision is real — fatigue, heat sensitivity (Uhthoff's phenomenon — a temporary dip in vision or other symptoms when the body warms up, whether from exercise, a hot shower, or fever), time of day, hydration, ambient light, and screen brightness all move the curve. A trend over many sessions averages over those, which is what makes the trend more useful than any one session.

What it can't tell you

Note. A contrast sensitivity test is a screening and tracking measurement, not a diagnosis.

It does not diagnose multiple sclerosis, optic neuritis, or any other condition.

It is not a substitute for optical coherence tomography, MRI, visual evoked potentials, or a clinical examination by a neuro-ophthalmologist or MS neurologist. Each of those measures something a contrast test does not.

A single measurement is a snapshot. Test-retest variation is real even with clinical instruments — the Pelli-Robson chart⁶ has a test-retest repeatability of about ±0.15 log units (a log unit is a tenfold change in contrast), and the smallest clinically meaningful change is generally taken to be about ±0.30 log units.⁷ A consumer-screen test, however carefully calibrated, is noisier than that.

Contrast sensitivity changes are not specific to MS. Cataract, glaucoma, refractive error, dry eye, diabetic retinopathy, post-concussion vision changes, fatigue, certain medications, and normal aging all reduce contrast sensitivity. The measurement cannot disambiguate. A clinical evaluation can.

A normal result does not rule out MS or MS-related visual change. Subclinical involvement can be present without a measurement on a home test catching it, and many things MS affects (motion perception, binocular vision, oculomotor control, vestibular-visual integration) are not what a CSF test measures.

The framing we'd ask you to hold: this is one piece of objective, longitudinal data you can collect at home and bring to the people who can actually examine you. It is not a substitute for that examination. It is a thread of evidence that the examination otherwise would not have access to.

Practical next steps

If you are reading this and have not yet taken a contrast sensitivity measurement, the practical sequence is:

1. Take the test now. Three minutes in the quick mode. Calibration happens at the start (screen size, viewing distance, gamma) so the numbers are comparable across sessions on the same device.
2. Save the result. Take a screenshot of the curve, or use the share-link generator to save a copy of the result.
3. Retake on a cadence that matches your situation. Monthly is a sensible default; weekly during active periods or around treatment changes; less often if you are stable.
4. Keep a one-line journal alongside the measurement. Fatigue level, time of day, room light, anything you have noticed visually. The journal is what makes the curve interpretable later.
5. Bring it to a neuro-ophthalmologist or your MS team. Many MS clinics already use low-contrast Sloan letters; the family of measurement is familiar territory there, and the trend over months adds context the clinic-day measurement cannot.

If you want the conceptual background on what a contrast sensitivity function is and what 20/20 leaves out, the primer post covers it. If you want the methodology specifics — how the calibration works, what the adaptive procedure does, how we render low-contrast patterns faithfully on a consumer screen — the methodology page does.

Take the test

Take the test now. Save the result. Re-take next month, and the month after. Bring the line to your next neuro-ophthalmology appointment.

A single result is a snapshot. The second is the start of a line, and the line is what your clinic visit can be built on.